Abstract: The invention relates to inhibitory compounds of a p38 MAP kinase having a structure of type (I)-(VII) which can be used for the treatment or prophylaxis of adhesion. Pharmaceutical compositions are disclosed containing an effective amount of the substance SB203580 or one or more of the conjugated compounds of type (I)-(VII) or a combination thereof, and a pharmaceutically acceptable carrier, a diluent or an excipient. Also disclosed is the use of the substance SB203580 as an agent having anti-adhesion activity. Also disclosed is a method for the prophylaxis and/or treatment of a disease or a condition in which there is a possibility of the formation and/or growth of adhesions, which makes it possible to dispense with the additional administration of a preparation in the post-operative period.

Abstract: A method for formulating a cleaning composition contains the step of coating a granular absorbent material with a coating agent to produce a coated absorbent material and mixing the coated absorbent material with a sanitation agent, wherein the coated absorbent material absorbs the sanitation agent to form the cleaning composition. The resulting cleaning composition may be used for cleaning up pathogens or hazardous materials. The cleaning composition may also functions as a liquefiable dry cleaning powder for public areas in response to bodily fluid incidents. A coating method of a non-toxic bio static film on a high surface area solid is disclosed.

Abstract: A novel acid labile linker for targeted delivery and/or controlled release of agents is introduced herein. There is further disclosed a method of developing a therapeutic or diagnostic conjugate for targeted cell-specific delivery. More specifically, the invention is focused on linkers used to deliver anticancer agents to specific tumor cells.

Abstract: A bio-synthetic matrix comprising a hydrogel which is formed by cross-linking a synthetic polymer and a bio-polymer is provided. The matrix is robust, biocompatible and non-cytotoxic and is capable of supporting cell in-growth in vivo. The matrix can be tailored to further comprise one or more bioactive agents. The matrix may also comprise cells encapsulated and dispersed therein, which are capable of proliferating upon deposition of the matrix in vivo. Methods of preparing the bio-synthetic matrix and the use of the matrix in vivo for tissue engineering or drug delivery applications are also provided.

Abstract: Described herein are platinum-based brush-arm star polymers (Pt-BASPs), or a pharmaceutical composition thereof, for delivery of platinum-based agents, such as cisplatin. Also provided are methods and kits involving the Pt-BASPs, or a pharmaceutical composition thereof, for treating proliferative diseases such as cancers (e.g., lung cancer, head-and-neck cancer, esophagus cancer, stomach cancer, breast cancer, pancreas cancer, liver cancer, kidney cancer, or prostate cancer) in a subject.

Abstract: The present invention provides, among other things, polymeric reagents suitable for reaction with biologically active agents to form conjugates, the polymeric reagents comprising one or more polymer chains and a plurality of hydroxyapatite-targeting moieties, and optionally the reagents include one or more degradable linkages that serve to divide the polymer chains into polymer segments having a molecular weight suitable for renal clearance.

Abstract: Provided herein is a method for enzymatically triggered assembly of polymeric nanostructures for detection of cancer-associated enzymes in vivo. By detecting enzymatic signals associated with disease, one can sensitively determine the site, and extent of disease within a patient.

Abstract: A method of coating surfaces of various body-implantable materials with control-releasable nitrogen monoxide using a catecholamine, more particularly, technology of preparing a coating film containing a diazeniumdiolate functional group on a surface of a material to be coated using a catecholamine, is provided. The coating film prepared by the method has advantages in that nitrogen monoxide can be stably supplied under an in vivo environment, and can be suitably used in a living body without causing cytotoxicity. Therefore, among the materials having a coating film formed on a surface thereof, the body-implantable material is especially expected to be widely used for medical and health applications including treatment of ischemic disorders such as arteriosclerosis through controlled release of nitrogen monoxide, regulation of penile erections, antibacterial and antiviral effects, and wound healing.

Abstract: A rotaxane consisting of a cucurbituril and an uncharged guest molecule, having low or null affinity therebetween is provided as well as processes for providing the same. Various uses as energy converters (“frictionless” molecular motors), biochips and biosensors using the same are also provided.

Abstract: The invention relates to inhibitory compounds of a p38 MAP kinase having a structure of type (I)-(VII) which can be used for the treatment or prophylaxis of adhesion. Pharmaceutical compositions are disclosed containing an effective amount of the substance SB203580 or one or more of the conjugated compounds of type (I)-(VII) or a combination thereof, and a pharmaceutically acceptable carrier, a diluent or an excipient. Also disclosed is the use of the substance SB203580 as an agent having anti-adhesion activity. Also disclosed is a method for the prophylaxis and/or treatment of a disease or a condition in which there is a possibility of the formation and/or growth of adhesions, which makes it possible to dispense with the additional administration of a preparation in the post-operative period.

Abstract: The present invention provides water soluble fullerene formulations and methods of use thereof.

Abstract: [Problems] To provide a novel taxane derivative which can release the medicinal substance in a bioenzyme-independent manner, is expected to have an effective therapeutic efficacy, and has a water-solubility. [Means for Solving Problems] Disclosed is a polymer conjugate of a taxane, which comprises a polymer having a polyethylene glycol moiety and two or more succinic acid monoamide moieties and a taxane, wherein a carboxylate group in the polymer and an alcoholic hydroxyl group in the taxane are bound to each other via an ester bonding.

Abstract: A device delivers a chemical or biological agent, the device comprises an imprint molecule (IM) to be delivered by the device; an electroactive molecularly imprinted polymer (EMIP) imprinted with the imprint molecule, the EMIP having a plurality of binding sites capable of binding the imprint; and an electric potential producing member (EPM), the EPM being capable of producing an electric potential between the EPM and the EMIP; whereby when the EMIP has a predetermined density of imprint molecule bound at the binding sites, and whereby when a sufficient potential is produced between the EPM and the EMIP, the imprint molecule is released from the binding site and thereby delivered by the device.

Abstract: A device delivers a chemical or biological agent, the device comprises an imprint molecule (IM) to be delivered by the device; an electroactive molecularly imprinted polymer (EMIP) imprinted with the imprint molecule, the EMIP having a plurality of binding sites capable of binding the imprint; and an electric potential producing member (EPM), the EPM being capable of producing an electric potential between the EPM and the EMIP; whereby when the EMIP has a predetermined density of imprint molecule bound at the binding sites, and whereby when a sufficient potential is produced between the EPM and the EMIP, the imprint molecule is released from the binding site and thereby delivered by the device.

Abstract: Therapeutic particles contain metal ions and are characterized by the use of unique ligand sets capable of making the metal ion complex soluble in biological media to induce selective toxicity in diseased cells. The particles may comprise a polymeric base particle, at least one pharmaceutically active metal ion, including metal ions from more than one metal element, a ligand that is covalently attached to the polymeric base particle and attached to the metal ion via a stimuli-responsive bond, and a cell targeting component. When the metal ion-containing particle enters a pre-defined environment, the ligands binding the metal to the particle are broken, triggering release of the free metal ion while the original ligands remain covalently bound to the particle.

Abstract: A composition comprising a structural component comprising linear acrylic homopolymers or linear acrylic copolymers and a biobeneficial component comprising copolymers having an acrylate moiety and a biobeneficial moiety is disclosed. A medical article comprising the composition in the coating thereof and a method of fabricating the medical article are also disclosed.

Abstract: Linear block ethylenic copolymer comprising: at least one block A derived from monomers comprising from 52 to 100 % by weight of an ethylenic monomer containing a lactam ring corresponding to formula (I) below: and at least one block B derived from monomers not comprising an ethylenic monomer containing a lactam ring of formula (I), or comprising a minor proportion thereof, the at least one block B having a glass transition temperature Tg ranging from ?55° C. to +55° C. Compositions and processes using the compound are also disclosed.

Abstract: The invention relates to the use of at least one copolymer obtainable by (i) free-radically initiated copolymerization of a monomer mixture comprising (a) 1 to 99.99% by weight of at least one monomer chosen from N-vinylimidazoles and diallylamines optionally in partially or completely quaternized form; (b) 0 to 98.99% by weight of at least one neutral or basic water-soluble monomer which is different form (a); (c) 0 to 50% by weight of at least one unsaturated acid or unsaturated anhydride, (d) 0 to 50% by weight of at least one free-radically copolymerizable monomer which is different from (a), (b) or (c); and (e) 0.01 to 10% by weight of at least one monomer which acts as crosslinker and has at least two ethylenically unsaturated, nonconjugated double bonds; and (ii) subsequent partial or complete quaternization or protonation of the polymer in the case where the monomer (a) is unquaternized or only partially quaternized, as additive for skin cosmetic and dermatological preparations.

Abstract: Mixed micelles containing poly(L-histidine)-poly(ethylene glycol) block copolymer and poly(L-lactic acid)-poly(ethylene glycol) block copolymer are a pH-sensitive drug carrier that release the drug in an acidic microenvironment, but not in the blood. Since the microenvironment of solid tumors is acidic, these mixed micelles are useful for treating cancer, including those cancers exhibiting multidrug resistance. Targeting ligands, such as folate, can also be attached to the mixed micelles for enhancing drug delivery into cells. Methods of making poly(L-histidine), synthetic intermediates, and block copolymers are also described.

Abstract: A polymer comprising: a polymeric backbone comprising at least one unit having the structure (I), wherein R-R4 comprise groups selected from the group consisting of H, C1-C12 alkyl, C6-C18 aryl, C7-C18 aralkyl, C6-C18 cycloalkyl or any of the group consisting of C1-C12 alkyl, C6-C18 aryl, C7-C18 aralkyl, C6-C18 cycloalkyl substituted, within the carbon chain or appended thereto, with one or more heteroatoms; R and R2 or R and R4 or R and R1 or R2 and R3 may be joined so that with the carbon atom(s) to which they are attached they together form a saturated, partially unsaturated or unsaturated ring system respectively, may have a pendent group which may incorporate a linker unit, (for example a peptide linkage) or a unit having the structure (I); A comprises a proton donating moiety selected from the group consisting of formula (1).

Abstract: Anticancer agents which contain as the active ingredient, a heme oxygenase inhibitory metalloporphyrin derivatives which are conjugated with amphipathic or water-soluble polymers (in particular, Zn-protoporphyrin (ZnPP) conjugated with polyethylene glycol). Because of being conjugated to amphipathic or water-soluble polymers, such as polyethylene glycol, the active ingredient can be administered by intravenous injection and can exert a remarkable anticancer effect owing to tumor selective delivery.

Abstract: The present invention provides a cationic group-containing amphiphilic block copolymer that is biocompatible and biodegradable, and when used as a drug carrier for an anionic drug, provides several advantages, such as increased blood concentration and improved stability of the drug.

Abstract: Use of a polyamino polymer to inhibit the light-induced peroxidation of lipids, particularly inhibition of the photo-peroxidation of lipids induced by nanopigments. The invention also relates to the use of a polyamino polymer to inhibit the light-induced peroxidation of proteins. This property of polyamino polymers finds applications in particular in the cosmetics, pharmaceutical, veterinary and agrifood fields.

Abstract: Facially amphiphilic polyphenylene and heteroarylene polymers and articles made therform having biocidal surfaces are disclosed. The polymers can inhibit the growth of microorganisms in contact with the surface or in areas adjacent to said biocidal surface. There is also disclosed a methods to attach facially amphiphilic polmers to a solid support. Utility as a contact disinfectant is disclosed.

Abstract: Transport reagents and conjugates of therapeutic agents linked to transport reagents are described. In particular, the transport reagents have a plurality of guanidinium moieties that are either contiguous or spaced along a backbone, but are sufficiently removed from the backbone via tethers, to allow their interaction with a cell or tissue surface, leading to uptake of the therapeutic agent.

Abstract: The present invention relates to compositions and methods involving biocompatible dendrimers. In particular, the present invention provides dendrimeric copolymers with poly(propyleneimine) (POPAM) interiors and poly(amidoamine) (PAMAM) exteriors for use in transfection and imaging applications.

Abstract: Methylated polystyrene having pendant N-halamine and N-halamine precursor groups. Biocidal particles have been prepared by reacting highly crosslinked methylated polystyrene beads as starting materials with various N-halamine precursor compounds. The resulting polymer beads are halogenated with chlorine or bromine. The porous beads will be useful in disinfection applications, as well as for sanitization and controlling noxious odor when mixed with absorbent materials in items such as disposable diapers, infant swimwear, incontinence pads, bandages, sanitary napkins, pantiliners, mattress covers, shoe inserts, sponges, animal litter, carpets, and fabrics.

Abstract: The present invention relates to purified platinum complexes in which platinum is coordinated to form a single N,O- or O,O-chelate of an amidomalonate. The chelates, and pharmaceutically acceptable formulations thereof, are useful for the treatment of cancer. The platinum chelates may additionally be linked to one or more functional groups which increases water solubility and/or assists in tumor targeting of the chelate. Examples of tumor targeting moieties include polymers, in which one or more platinum chelates are attached to the polymer backbone via linkers capable of being cleaved in the body, and molecules with a high affinity for receptors which are concentrated or upregulated in tumor tissue and/or the tumor vasculature.

Abstract: The present invention describes the application of sirolimus and analogs of sirolimus to treat wound healing and reduce scar tissue formation. Also contemplated are non-sirolimus compounds believed to interact with the mTOR protein that have similar effects. Specifically, various medium are contemplated to create, for example, microparticles, foams, gels, sprays and bioadhesives that may be administered during surgical procedures involving either open or closed surgical site. Coating medical devices for long-term implantation is contemplated as one method of use of the above compositions.

Abstract: This invention relates to a non-leachable, oil based carrier derived from the anhydrous free radical solution polymerization of a water insoluble acrylate and/or acrylamide monomer in an oil medium for use in long lasting skin lubricating formulations.

Abstract: Use of a polyamino polymer to inhibit the light-induced peroxidation of lipids, particularly inhibition of the photo-peroxidation of lipids induced by nanopigments. The invention also relates to the use of a polyamino polymer to inhibit the light-induced peroxidation of proteins. This property of polyamino polymers finds applications in particular in the cosmetics, pharmaceutical, veterinary and agrifood fields.

Abstract: Transport reagents and conjugates of therapeutic agents linked to transport reagents are described. In particular, the transport reagents have a plurality of guanidinium moieties that are either contiguous or spaced along a backbone, but are sufficiently removed from the backbone via tethers, to allow their interaction with a cell or tissue surface, leading to uptake of the therapeutic agent.

Abstract: A composition capable of forming a micelle in body fluids or in an aqueous medium and that can be injected into the body undiluted or as a diluted solution in an aqueous medium and method of preparation are disclosed. The composition comprises an amphiphilic block copolymer having a hydrophilic poly(alkyleneglycol) component and hydrophobic biodegradable polymer component, suspended in a poly (alkyleneglycol) medium. Such composition is used in the solubilization and administration of a poorly water-soluble drug.

Abstract: The present invention is a method of using a polymeric N-halamine biocidal material as an agent preferably used in conjunction with a matrix material for the reduction of noxious odors caused by the decomposition of organic compounds. In a preferred embodiment of the method according to the present invention, the biocidal N-halamine polymer is provided in a comminuted form and mixed with super absorbent polymer to provide a treatment composition. The treatment composition is emplaced within an article to provide intimate contact between the composition and a microorganism-containing fluid.

Abstract: The present invention provides combinations of cardiovascular therapeutic compounds for the prophylaxis or treatment of cardiovascular disease including hypercholesterolemia and atherosclerosis. Combinations disclosed include an cholesteryl ester transfer protein inhibitor combined with a bile acid sequestrant.

Abstract: Bactericidal compositions are disclosed that comprise a polymeric compound immobilized on a material. Medical devices are also disclosed which comprise such a bactericidal composition. Methods are disclosed for covalently derivatizing the surfaces of common materials with an antibacterial polycation, e.g., poly(vinyl-N-pyridinium bromide); the first step of the methods involves coating the surface with a nanolayer of silica. Various commercial synthetic polymers derivatized in this manner are bactericidal, i.e., they kill on contact up to 99% of deposited Gram-positive and Gram-negative bacteria, whether deposited through air or water.

Abstract: A prion-physiological structure and associated method of formation. A provided abnormal prion has a transforming power over a normal prion to convert the abnornal prion into defective prion that mimics the abnormal prion. A linker molecule is then bonded to the abnormal prion, wherein a polymer that is covalently attached to the linker molecule facilitates formation of a polymerized abnormal prion that does not have the transforming power over the normal prion.

Abstract: N-halamine biocidal materials and coatings are provided. Monomeric oxazolidinones or hydantoins are homopolymerized or copolymerized with other monomers so as to produce materials or coatings, which upon exposure to solutions of chlorine or bromine become biocidal. The biocidal materials and coatings are effective at inactivating microorganisms upon surface contact and are regenerable following loss of efficacy upon further exposure to solutions of chlorine or bromine. Surfaces which could be treated with the materials and coatings include, but are not limited to: glass, plastic, metals, fibers, and wood for use in pool and tank liners, food wrappers, catheters, paints, tiles, shower walls, fabrics, sterile bandages, pipes, medical and dental coatings, preservatives, and the like.

Abstract: Method for preparing biocidal halogenated polystyrene hydantoins. The biocidal polymers poly-1,3-dichloro-5-methyl-5-(4′-vinylphenyl)hydantoin, poly-1,3-dibromo-5-methyl-5-(4′-vinylphenyl)hydantoin, and their monohalogenated alkali metal salts and protonated derivatives have been prepared as porous beads by use of highly crosslinked polystyrene beads as starting materials. The porous beads will be useful in water and air disinfection applications when employed in cartridge filters and carafes (for water), as well as for controlling noxious odor when mixed with absorbent materials in items such as disposable diapers, incontinence pads, bandages, sanitary napkins, pantiliners, mattress covers, shoe inserts, sponges, animal litter, carpets, fabrics, and air filters or the like.

Abstract: N-halamine biocidal materials and coatings are provided. Monomeric oxazolidinones or hydantoins are homopolymerized or copolymerized with other monomers so as to produce materials or coatings, which upon exposure to solutions of chlorine or bromine become biocidal. The biocidal materials and coatings are effective at inactivating microorganisms upon surface contact and are regenerable following loss of efficacy upon further exposure to solutions of chlorine or bromine. Surfaces which could be treated with the materials and coatings include, but are not limited to: glass, plastic, metals, fibers, and wood for use in pool and tank liners, food wrappers, catheters, paints, tiles, shower walls, fabrics, sterile bandages, pipes, medical and dental coatings, preservatives, and the like.

Abstract: A carrier for stabilizing a nucleic acid is provided which forms a soluble, stable complex with a nucleic acid, which has a stabilizing effect on a double or triple helix of a nucleic acid, which suppresses the structural change of a nucleic acid, and which enables the reversibility of a nucleic acid to be retained. A method for stabilizing a nucleic acid by use of such a carrier is also provided. This carrier is a polymer having a poly(cationic amino acid) as a main chain, and a comb-shaped hydrophilic group as a side chain modifying the polymer.

Abstract: A process of making a cosmetically or pharmaceutically-acceptable emulsion or gel composition which comprises: (a) heating a reaction mixture comprising, by weight, about 5-70% of a vinyl monomer in about 30-95% of an oil as solvent, wherein said oil is selected from the group consisting of a silicone oil, a mineral oil and a water-insoluble organic ester and a free radical initiator, optionally in the presence of a crosslinking agent and/or an oil soluble surfactant, with agitation, under an inert gas, at about 40-150° C., wherein the oil is present in an amount sufficient to keep the resultant vinyl polymer in a stirrable state until the end of the polymerization, (b) adding a surfactant, if a suitable surfactant was not present during polymerization, and, (c) then adding water to form an oil-in-water, a water-in-oil or a water-in-oil-in-water emulsion or gel, in a volume ratio of oil-in-water of 30:70 to 10:90, or water-in-oil of 90:10 to 30:70.

Abstract: Complexes in powder form of iodine and a crosslinked polymer based on N-vinyl compounds are obtainable by dry heating of iodine and a polymer which is obtained by polymerization of monovinyl compounds (monomers A) whose vinyl group is bonded to a nitrogen atom of a nitrogen-containing heterocycle, in the presence of from 0.5 to 10% by weight, based on the monomers (A), of a compound (B) of the formula I; where A is —CH— or a nitrogen atom, and n is 2 or 3. The complexes are suitable for producing antidiarrheals.